Bristol-Myers Squibb
ImClone gets $250M related to FDA approval of ERBITUX
Published in FDA Law Weekly, April 15th, 2004
The cash payment was triggered by U.S. Food and Drug Administration approval of ERBITUX to treat irinotecan-refractory or intolerant-metastatic EGFR-expressing colorectal cancer on February 12, 2004.
"This milestone payment represents the acknowledgement by Bristol-Myers Squibb of the progress that we have made together in the ERBITUX clinical program, which culminated in the recent approval of the drug in combination with irinotecan and as a single agent in certain patients with late-stage colorectal cancer," stated...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
Source: FDA Law Weekly (2004-04-15)
More Articles from FDA Law Weekly
- Allos Therapeutics, Inc.
NDA for radiation therapy sensitizer to be reviewed by FDA panel - Centers for Medicare & Medicaid Services
Giving antibiotics within 4 hours of arrival at a hospital improves outcomes - Closure Medical Corporation
FDA approves commencement of vascular sealant study - Coapt Systems, Inc.
Endotine Midface ST 4.5 launched for surgical midface suspension - Cutting Edge Information
Generic pharmaceutical industry anticipates double-digit growth - Cygnus, Inc.
GlucoWatch G2 Biographer receives FDA approval to expand labeling - More from this issue of FDA Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
